Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	14 September 2020
Date of last disclosure:	6 July 2020

Director or senior manager giving disclosure

Full name(s):	**Lewis George GRADON**
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	(a) Options to acquire Ordinary Shares (b) Performance Share Rights (c) Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest:	
Number held in class before acquisition or disposal:	(a) 350,504 Options to acquire Ordinary Shares (b) 140,912 Performance Share Rights (c) 553,649 Ordinary Shares
Number held in class after acquisition or disposal:	(a) 309,071 Options to acquire Ordinary Shares (b) 98,492 Performance Share Rights (c) 556,776 Ordinary Shares
Current registered holder(s):	Lewis George Gradon and Gradon Family Trust
Registered holder(s) once transfers are registered:	Lewis George Gradon and Gradon Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative:	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure:	
Date of transaction:	(a) 04 & 08 September 2020 (b) 04 & 10 September 2020 (c) 08, 09 & 10 September 2020
Nature of transaction:	(a) Issue of 69,931 Options; cancellation of 111,364 Options and issue of 73,529 Ordinary Shares (b) Issue of 22,178 PSRs; exercise of 64,598 PSRs and issue of 64,598 Ordinary Shares (c) Sale of 135,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):	

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	(a) $nil (b) $nil (c) $4,565,936.00
Number of financial products to which the transaction related:	(a) 69,931 Options to acquire Ordinary Shares; 111,364 Options to acquire Ordinary Shares and 73,529 Ordinary Shares (b) 22,178 PSRs; 64,598 PSRs and 64,598 Ordinary Shares (c) 135,000 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal

Class of quoted financial products:	
Nature of relevant interest:	

For that relevant interest:

Number held in class:	
Current registered holder(s):	

For a derivative relevant interest:

Type of derivative:	Not Applicable

Details of derivative:

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	14 September 2020

or

Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

NZX

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	14 September 2020
Date of last disclosure:	25 September 2019

Director or senior manager giving disclosure

Full name(s):	Lyndal Jane York
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in listed issuer:	Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	(a) Performance Share Rights (b) Options to acquire Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial
For that relevant interest	
Number held in class before acquisition or disposal:	(a) 9,406 (b) 29,781
Number held in class after acquisition or disposal:	(a) 15,275 (b) 48,285
Current registered holder(s):	Lyndal Jane York
Registered holder(s) once transfers are registered:	Lyndal Jane York

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure-	
Date of transaction:	(a) 04 September 2020 (b) 04 September 2020
Nature of transaction:	(a) Issue of 5,869 Performance Share Rights (b) Issue of 18,504 Options to acquire Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	(a) $0 (b) $0
Number of financial products to which the transaction related:	(a) 5,869 (b) 18,504

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were aquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	Ordinary Shares
Nature of relevant interest:	Beneficial
For that relevant interest,-	
Number held in class:	1,000
Current registered holder(s):	Alexander Eric York
For a derivative relevant interest,-	
Type of derivative:	Not Applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Cerification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	14 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	